SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934



Date of Report: March 3, 2004

                             -----------------------

                              HYCOR BIOMEDICAL INC.

             (Exact name of registrant as specified in its charter)

                                     0-11647
                            (Commission File Number)


              Delaware                              58-1437178
    (State or other jurisdiction of              (I.R.S. Employer
     incorporation or organization)             Identification No.)



                                7272 Chapman Ave
                         Garden Grove, California 92841
             (Address of principal executive offices, with zip code)

                                 (714) 933-3000
              (Registrant's telephone number, including area code)








Item 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

       (c) EXHIBITS

           99.1     Press Release dated February 25, 2004

Item 9.  REGULATION FD DISCLOSURE

         On February 26, 2004, Hycor Biomedical Inc issued a press release
         reporting its financial results for the quarter ended December 31,
         2003. A copy of the press release is attached hereto as Exhibit 99.1
         and is incorporated herein by reference. This information is being
         furnished under both Item 9 (Regulation FD Disclosure) and Item 12
         (Results of Operations and Financial Condition) of Form 8-K and is
         included under this Item 9 in accordance with SEC Release No. 33-8126.
         This information shall not be deemed "filed" for purposes of Section 18
         of the Securities Exchange Act of 1934, as amended (the "Exchange
         Act"), or incorporated by reference in any filing under the Securities
         Act of 1933, as amended, or the Exchange Act, except as shall be
         expressly set forth by specific reference in such a filing.



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                          Hycor Biomedical Inc.

Date:    March 3, 2004           By: /s/ Reg Jones___________________
                                   ----------------------------------
                                   Reg Jones
                                   Executive Vice President and Chief Financial
                                   Officer (Principal Financial Officer)









                                INDEX TO EXHIBITS


Exhibit Number                                       Description
--------------                                       -----------
        99.1                              Press Release dated February 25, 2004